Category: Pfizer
-
BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+
Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each.